NCT03480126 (OsTea) is a NA clinical trial of Herbal Teas in Osteopenia, sponsored by Paula Witt-Enderby.

Who is sponsoring NCT03480126?

NCT03480126 is sponsored by Paula Witt-Enderby.

What drugs are being tested in NCT03480126?

Interventions in NCT03480126: Herbal Teas.

What condition does NCT03480126 study?

NCT03480126 studies Osteopenia.

Is NCT03480126 still recruiting?

NCT03480126 is currently completed. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT03480126: OsTea

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Herbal Teas on Bone Health in an Osteopenic Population

Completed NA Last updated 11 January 2022

What this trial tests

NA trial testing Herbal Teas in Osteopenia in 35 participants. Completed in 27 August 2019.

Timeline

1 June 2018

Primary endpoint
27 August 2019

27 August 2019

Quick facts

Lead sponsor	Paula Witt-Enderby
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	35
Start date	1 June 2018
Primary completion	27 August 2019
Estimated completion	27 August 2019
Sites	1 location across United States

Drugs / interventions tested

Herbal Teas

Conditions studied

Osteopenia — all drugs for Osteopenia →

Sponsor

Paula Witt-Enderby

Who can join

18 and older, any sex, with Osteopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project goal is to identify if herbal teas consumed three times per day over a period of three months can improve these markers of bone health as well as improve quality of life (QOL) compared to women taking placebo by increasing osteoblast activity, decreasing osteoclast activity, increasing nocturnal melatonin levels and by decreasing C-reactive protein (CRP) and cortisol levels. Our central hypothesis is that these herbal teas will improve both objective and subjective measures of bone health in a population with osteopenia not taking this regimen by reducing osteoclast activity and increasing osteoblast activity and by reducing stress and anxiety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Osteopenia

Currently open trials in the same condition.

NCT07473713 — Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia · Phase 1 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
NCT07187518 — Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device · NA · recruiting
NCT07191353 — Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03480126 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paula Witt-Enderby
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03480126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing